As previously reported, Truist analyst Jailendra Singh downgraded R1 RCM to Hold from Buy with an unchanged price target of $15. The near to medium-term risk-reward seems "relatively more balanced," said the firm, which views R1 RCM as a "show me story" in 2023 with expectations "no longer low."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RCM:
- R1 RCM downgraded to Hold from Buy at Truist
- R1 RCM to Release Fourth Quarter 2022 Results on February 16
- R1 RCM Announces Leadership Appointments; Reaffirms 2022 Guidance and Announces 2023 Outlook
- R1 RCM initiated with a Buy at Canaccord
- R1 RCM to Present at the 41st Annual J.P. Morgan Health Care Conference
